Please assess the completion status of the following clinical trial:

Trial Title: Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~A subject must fulfil the following criteria in order to be included in the study:~1. FMF diagnosed as per the Tel-Hashomer criteria -(Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum.1998 Aug; 41(8):1516-7-Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M).~2. 18-65 years of age~3. Verified as mutations in both alleles of the MEFV gene, thus including homozygous and compound heterozygous patients~4. Patient compliant with maximum tolerable dose of colchicine (up to 3 mg/day)~5. At least one FMF attack per month in chest, abdomen or joints (definition of attack see above)~6. Adequate contraception for sexually active male and female patients~Exclusion Criteria:~The presence of any of the following will exclude a subject from inclusion in the study:~1. Patient pregnant at enrolment visit~2. Prior or existing malignancy~3. Active infection~4. Manifest renal failure with Creatinine clearance \<30mL/min as determined by the equation Creatinine clearance (ml/min) = (140-age) x Wight (Kg) /72 x serum creatinine (mg/dcl) For women one should multiply the results by 0.8~5. Live vaccinations last three months before enrolment~6. Sociopsychological state threatening compliance with the treatment protocol~7. Alcohol or substance abuse~8. Concomitant medication with biological or anti-rheumatic disease-modifying drugs or systemic steroids~9. Any prior use of IL-1 inhibitory drugs~10. Associated disease that could interfere with clinical assessment:~    1. Rheumatic disorder~   2. Systemic disease, e.g. autoimmune or other autoinflammatory disorder, diabetes, hypertension, vasculitis, Behçet's disease~   3. Gastrointestinal disorder, e.g. Crohn's disease, ulcerative colitis, irritable bowel syndrome~   4. Cardiovascular disorder, e.g. post myocardial infarction, angina~   5. Pulmonary disorder, e.g. COPD, pulmonary hypertension~   6. Any other condition which in the opinion of the investigator makes the subject unsuitable for inclusion~11. Enrolment in another concurrent clinical study, or intake of an investigational drug, within three months prior to inclusion in this study~12. Failure or refusal to cooperate with given instructions~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vehicle (Type: PLACEBO_COMPARATOR): •Patients randomized to placebo will receive syringes identical to active drug (100 mg prefilled syringes for subcutaneous injection) filled with drug vehicle
- Kineret (Anakinra) (Type: EXPERIMENTAL): Patients randomized to active drug will receive Kineret (Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete